Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CRBP
- CUSIP: N/A
- Web: www.corbuspharma.com
Capitalization:- Market Cap: $321.4 million
- Outstanding Shares: 50,218,000
Average Prices:- 50 Day Moving Avg: $6.35
- 200 Day Moving Avg: $7.28
- 52 Week Range: $2.76 - $10.78
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.70
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.81 million
- Price / Sales: 114.38
- Book Value: $0.87 per share
- Price / Book: 7.36
Profitability:- EBIDTA: ($24,450,000.00)
- Net Margins: -874.41%
- Return on Equity: -117.78%
- Return on Assets: -88.66%
Debt:- Current Ratio: 7.21%
- Quick Ratio: 7.21%
Misc:- Average Volume: 669,246 shs.
- Beta: 2.53
- Short Ratio: 10.28
Frequently Asked Questions for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
What is Corbus Pharmaceuticals Holdings' stock symbol?
Corbus Pharmaceuticals Holdings trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals Holdings' earnings last quarter?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Tuesday, May, 9th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm earned $1.29 million during the quarter, compared to analyst estimates of $2.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 874.41% and a negative return on equity of 117.78%. View Corbus Pharmaceuticals Holdings' Earnings History.
When will Corbus Pharmaceuticals Holdings make its next earnings announcement?
Where is Corbus Pharmaceuticals Holdings' stock going? Where will Corbus Pharmaceuticals Holdings' stock price be in 2017?
4 equities research analysts have issued twelve-month price targets for Corbus Pharmaceuticals Holdings' shares. Their predictions range from $12.00 to $27.00. On average, they expect Corbus Pharmaceuticals Holdings' share price to reach $20.50 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals Holdings.
Who are some of Corbus Pharmaceuticals Holdings' key competitors?
Some companies that are related to Corbus Pharmaceuticals Holdings include Versartis (VSAR), MacroGenics (MGNX), REGENXBIO (RGNX), Paratek Pharmaceuticals (PRTK), NantKwest (NK), Audentes Therapeutics (BOLD), Alder BioPharmaceuticals (ALDR), Otonomy (OTIC), Achillion Pharmaceuticals (ACHN), Seres Therapeutics (MCRB), AnaptysBio (ANAB), Calithera Biosciences (CALA), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Ignyta (RXDX), Sucampo Pharmaceuticals (SCMP), CytomX Therapeutics (CTMX) and Dynavax Technologies Corporation (DVAX).
Who are Corbus Pharmaceuticals Holdings' key executives?
Corbus Pharmaceuticals Holdings' management team includes the folowing people:
- Mark A. Tepper Ph.D., President, Chief Scientific Officer
- Yuval Cohen Ph.D., Chief Executive Officer, Director
- Sean F. Moran CPA, Chief Financial Officer
- Barbara White M.D., Chief Medical Officer
- David P Hochman, Director
- Avery W. Catlin CPA, Independent Director
- Renu Gupta M.D., Independent Director
- Alan F. Holmer J.D., Independent Director
Who owns Corbus Pharmaceuticals Holdings stock?
Corbus Pharmaceuticals Holdings' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Creative Planning (0.35%), Woodstock Corp (0.11%) and Evanson Asset Management LLC (0.04%). Company insiders that own Corbus Pharmaceuticals Holdings stock include Alan F Holmer, Avery W Catlin, Barbara White, David P Hochman, Renu Gupta, Sean F Moran, Sumner Burstein and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals Holdings.
Who bought Corbus Pharmaceuticals Holdings stock? Who is buying Corbus Pharmaceuticals Holdings stock?
Corbus Pharmaceuticals Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning and Evanson Asset Management LLC. Company insiders that have bought Corbus Pharmaceuticals Holdings stock in the last two years include Alan F Holmer, Avery W Catlin, Barbara White, David P Hochman, Renu Gupta, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals Holdings.
How do I buy Corbus Pharmaceuticals Holdings stock?
Shares of Corbus Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals Holdings' stock price today?
One share of Corbus Pharmaceuticals Holdings stock can currently be purchased for approximately $6.40.
MarketBeat Community Rating for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)Earnings History by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/14/2017 | | ($0.19) | | | | | N/A |  |
| 5/9/2017 | Q1 2017 | ($0.16) | ($0.16) | $2.50 million | $1.29 million | View | N/A | |
| 3/9/2017 | Q4 2016 | ($0.12) | ($0.18) | $1.50 million | $0.38 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.10) | ($0.12) | $1.00 million | $0.74 million | View | N/A | |
| 8/15/2016 | Q216 | ($0.08) | ($0.11) | $1.25 million | $0.40 million | View | N/A | |
| 5/16/2016 | Q116 | ($0.08) | ($0.08) | | $0.40 million | View | N/A | |
| 11/10/2015 | Q315 | ($0.08) | ($0.06) | | $0.17 million | View | N/A | |
| 8/13/2015 | Q2 2015 | ($0.06) | ($0.10) | | $0.11 million | View | N/A | |
| 2/10/2015 | Q4 2014 | ($0.03) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
Dividend History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 28.06%
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/11/2017 | Barbara White | Insider | Buy | 2,435 | $6.12 | $14,902.20 | |
| 5/11/2017 | David P Hochman | Director | Buy | 3,400 | $6.18 | $21,012.00 | |
| 5/11/2017 | Sean F Moran | CFO | Buy | 3,300 | $6.14 | $20,262.00 | |
| 5/11/2017 | Yuval Cohen | CEO | Buy | 3,250 | $6.01 | $19,532.50 | |
| 3/17/2017 | Barbara White | Insider | Buy | 4,233 | $9.49 | $40,171.17 | |
| 3/13/2017 | Sean F Moran | CFO | Buy | 2,000 | $9.60 | $19,200.00 | |
| 12/2/2016 | Sean F Moran | CFO | Buy | 1,500 | $7.20 | $10,800.00 | |
| 11/22/2016 | Alan F Holmer | Director | Buy | 1,000 | $7.49 | $7,490.00 | |
| 11/22/2016 | Yuval Cohen | CEO | Buy | 1,340 | $7.64 | $10,237.60 | |
| 11/18/2016 | David P Hochman | Director | Buy | 10,000 | $7.00 | $70,000.00 | |
| 9/8/2016 | Sean F Moran | CFO | Buy | 30,800 | $5.12 | $157,696.00 | |
| 8/26/2016 | Sean F Moran | CFO | Buy | 17,900 | $3.92 | $70,168.00 | |
| 8/22/2016 | David P Hochman | Director | Buy | 1,800 | $3.77 | $6,786.00 | |
| 8/18/2016 | Sean F Moran | CFO | Buy | 148,960 | $3.32 | $494,547.20 | |
| 8/17/2016 | Barbara White | Insider | Buy | 38,000 | $3.15 | $119,700.00 | |
| 6/8/2016 | Barbara White | Insider | Buy | 1,935 | $3.10 | $5,998.50 | |
| 6/6/2016 | Yuval Cohen | CEO | Buy | 1,500 | $3.34 | $5,010.00 | |
| 6/1/2016 | Barbara White | Insider | Buy | 2,570 | $3.52 | $9,046.40 | |
| 5/19/2016 | Sean F Moran | CFO | Buy | 27,250 | $2.37 | $64,582.50 | |
| 5/18/2016 | Sean F Moran | CFO | Buy | 30,000 | $2.39 | $71,700.00 | |
| 5/18/2016 | Yuval Cohen | CEO | Buy | 2,125 | $2.40 | $5,100.00 | |
| 12/11/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.56 | $1,560.00 | |
| 12/10/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.61 | $1,610.00 | |
| 12/9/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.67 | $1,670.00 | |
| 12/8/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.68 | $1,680.00 | |
| 12/7/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.69 | $1,690.00 | |
| 12/4/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.72 | $1,720.00 | |
| 12/2/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.79 | $1,790.00 | |
| 11/24/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.78 | $2,670.00 | |
| 11/20/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.70 | $2,550.00 | |
| 11/19/2015 | Barbara White | Insider | Buy | 4,000 | $1.67 | $6,680.00 | |
| 11/18/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.71 | $2,565.00 | |
| 11/17/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.72 | $2,580.00 | |
| 11/16/2015 | Sean F Moran | CFO | Buy | 2,000 | $1.69 | $3,380.00 | |
| 9/16/2015 | Sean F Moran | CFO | Buy | 5,000 | $2.12 | $10,600.00 | |
| 9/15/2015 | Sean F Moran | CFO | Buy | 5,000 | $2.14 | $10,700.00 | |
| 9/14/2015 | Sean F Moran | CFO | Buy | 5,000 | $1.96 | $9,800.00 | |
| 9/11/2015 | Sean F Moran | CFO | Buy | 5,000 | $1.85 | $9,250.00 | |
| 9/3/2015 | Barbara White | Insider | Buy | 10,000 | $1.84 | $18,400.00 | |
| 8/25/2015 | Barbara White | Insider | Buy | 6,000 | $1.87 | $11,220.00 | |
| 8/21/2015 | Barbara White | Insider | Buy | 10,000 | $2.05 | $20,500.00 | |
| 8/21/2015 | Sean F Moran | CFO | Buy | 1,400 | $2.06 | $2,884.00 | |
| 8/19/2015 | Sumner Burstein | Major Shareholder | Sell | 200,000 | $3.04 | $608,000.00 | |
| 8/18/2015 | Barbara White | insider | Buy | 20,000 | $1.90 | $38,000.00 | |
| 8/18/2015 | Renu Gupta | Director | Buy | 10,000 | $1.89 | $18,900.00 | |
| 8/18/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.92 | $1,920.00 | |
| 8/17/2015 | Avery W Catlin | Director | Buy | 11,788 | $1.94 | $22,868.72 | |
| 8/17/2015 | Yuval Cohen | CEO | Buy | 2,100 | $1.92 | $4,032.00 | |
| 7/15/2015 | Sumner Burstein | Major Shareholder | Sell | 30,000 | $2.82 | $84,600.00 | |
| 6/15/2015 | Barbara White | Insider | Buy | 2,250 | $3.25 | $7,312.50 | |
| 6/12/2015 | Barbara White | Insider | Buy | 6,000 | $3.00 | $18,000.00 | |
| 6/9/2015 | Avery W Catlin | Director | Buy | 20,000 | $3.10 | $62,000.00 | |
| 6/9/2015 | Sean F Moran | CFO | Buy | 6,500 | $3.00 | $19,500.00 | |
| 12/18/2014 | Sean F Moran | CFO | Buy | 18,800 | $3.36 | $63,168.00 | |
| 12/17/2014 | Sean F Moran | CFO | Buy | 2,850 | $3.46 | $9,861.00 | |
| 12/11/2014 | Sean F Moran | CFO | Buy | 1,000 | $3.98 | $3,980.00 | |
| 12/9/2014 | Sean F Moran | CFO | Buy | 1,700 | $3.98 | $6,766.00 | |
| 12/4/2014 | Barbara White | Insider | Buy | 3,300 | $3.00 | $9,900.00 | |
| 12/4/2014 | David P Hochman | Director | Buy | 1,300 | $3.05 | $3,965.00 | |
| 12/4/2014 | Sean F Moran | CFO | Buy | 2,000 | $3.20 | $6,400.00 | |
| 12/3/2014 | Yuval Cohen | CEO | Buy | 1,000 | $3.20 | $3,200.00 | |
| 12/2/2014 | Sean F Moran | CFO | Buy | 1,000 | $3.03 | $3,030.00 | |
| 12/1/2014 | Barbara White | Insider | Buy | 16,448 | $3.00 | $49,344.00 | |
| 11/28/2014 | Barbara White | Insider | Buy | 19,933 | $3.00 | $59,799.00 | |
| 11/26/2014 | Barbara White | Insider | Buy | 13,400 | $3.00 | $40,200.00 | |
| 11/26/2014 | Sean F Moran | CFO | Buy | 1,000 | $3.05 | $3,050.00 | |
| 11/25/2014 | Mark Tepper | Insider | Buy | 2,000 | $3.05 | $6,100.00 | |
| 11/25/2014 | Sean F Moran | CFO | Buy | 3,000 | $3.05 | $9,150.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Latest Headlines for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
| Source: |
|
| Date | Headline |
|---|
 | How To Profit From Canada’s $22 Billion Marijuana Boom
finance.yahoo.com - July 19 at 11:41 PM |
 | Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - July 17 at 4:04 PM |
| ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 7:33 PM |
 | Cannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements - PR Newswire (press release)
www.prnewswire.com - July 11 at 6:37 PM |
| Corbus Pharmaceuticals Holdings, Inc. – Value Analysis (NASDAQ:CRBP) : July 11, 2017
finance.yahoo.com - July 11 at 6:37 PM |
| Corbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bullish Manner : CRBP-US : July 10, 2017
finance.yahoo.com - July 10 at 5:30 PM |
| BidaskClub Upgrades Corbus Pharmaceuticals Holdings, Inc. (CRBP) to "Hold"
www.americanbankingnews.com - July 8 at 8:26 PM |
 | Commit To Buy Corbus Pharmaceuticals Holdings At $5, Earn 17.2 ... - TheStreet.com
www.thestreet.com - July 7 at 4:53 AM |
| Corbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index
finance.yahoo.com - June 26 at 5:14 PM |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) Expected to Earn FY2018 Earnings of ($0.66) Per Share
www.americanbankingnews.com - June 26 at 10:42 AM |
 | Corbus Pharmaceuticals Can Hit New Highs By Year's End - Seeking Alpha
seekingalpha.com - June 23 at 10:06 PM |
| Noble Financial Reiterates Buy Rating for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
www.americanbankingnews.com - June 17 at 7:16 AM |
 | Corbus Pharma (CRBP) Announces Data from Phase 2 Study of ... - StreetInsider.com
www.streetinsider.com - June 16 at 4:26 AM |
 | BRIEF-Corbus Pharmaceuticals presented data from phase 2 study of anabasum for treatment of systemic sclerosis
www.reuters.com - June 15 at 6:22 PM |
| Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting
finance.yahoo.com - June 15 at 6:22 PM |
| ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : June 14, 2017
finance.yahoo.com - June 14 at 5:23 PM |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - June 13 at 5:56 PM |
| Marijuana Stocks Be Warned: Nevada's Recreational Weed Law May Have a Big Issue
finance.yahoo.com - June 10 at 4:41 PM |
| Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
finance.yahoo.com - June 8 at 5:30 PM |
| Corbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bullish Manner : CRBP-US : June 6, 2017
finance.yahoo.com - June 6 at 4:43 PM |
| Corbus Pharmaceuticals to Present at the 2017 Jefferies Global Healthcare Conference
finance.yahoo.com - June 1 at 5:05 PM |
| ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:19 PM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) Short Interest Update
www.americanbankingnews.com - May 22 at 2:46 PM |
| Top 4 Marijuana Stocks to Watch for 2017
finance.yahoo.com - May 18 at 4:24 PM |
| Noble Financial Reiterates Buy Rating for Corbus Pharmaceuticals Holdings Inc (CRBP)
www.americanbankingnews.com - May 14 at 8:45 AM |
| Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Purchases 3,400 Shares of Stock
www.americanbankingnews.com - May 12 at 4:46 PM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) CFO Sean F. Moran Buys 3,300 Shares
www.americanbankingnews.com - May 12 at 4:46 PM |
| Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Buys 2,435 Shares of Stock
www.americanbankingnews.com - May 12 at 10:17 AM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) CEO Yuval Cohen Purchases 3,250 Shares
www.americanbankingnews.com - May 12 at 10:16 AM |
| Corbus Pharma (CRBP) Says Last Subject Enrolled in Phase 2 Study of Anabasum - StreetInsider.com
www.streetinsider.com - May 11 at 5:07 PM |
| Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
finance.yahoo.com - May 11 at 5:07 PM |
| Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
finance.yahoo.com - May 11 at 5:07 PM |
| ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:07 PM |
| ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:07 PM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 12:04 AM |
| Corbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 4:41 PM |
| Today's Research Reports on Corbus Pharmaceuticals and Pluristem Therapeutics Post Earnings
finance.yahoo.com - May 10 at 8:10 AM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 11:36 PM |
| Corbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 4:29 PM |
 | Corbus Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 9:22 AM |
| The Creation of Jobs in the Legal Cannabis Market
www.prnewswire.com - May 5 at 4:41 PM |
| Corbus Pharmaceuticals Holdings (CRBP) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 1:15 AM |
| Read This Before You Buy Biotech Stocks
finance.yahoo.com - May 1 at 8:25 AM |
| Corbus Pharmaceuticals Holdings (CRBP) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 7:26 PM |
| Corbus Pharmaceuticals Holdings (CRBP) Earning Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 5:07 PM |
| Corbus Pharmaceuticals Holdings (CRBP) Given Daily Coverage Optimism Rating of 0.23
www.americanbankingnews.com - April 20 at 4:52 PM |
| Corbus Pharmaceuticals Holdings (CRBP) Earns Media Sentiment Rating of 0.24
www.americanbankingnews.com - April 14 at 9:22 AM |
| Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma - PR Newswire (press release)
www.prnewswire.com - April 12 at 8:18 AM |
| Did Corbus Investors Get Thrown Off by a Red Herring?
finance.yahoo.com - April 10 at 4:20 PM |
| What's Next for Corbus Pharmaceuticals After Its Controversial Cystic Fibrosis Results?
finance.yahoo.com - April 8 at 4:23 PM |
Corbus Pharmaceuticals Holdings (CRBP) Chart for Sunday, July, 23, 2017
